Flow Pharma Overview
- Founded
-
2002
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$180K
- Investors
-
8
Flow Pharma General Information
Description
Developer of immunotherapy platform designed to offer curative intervention in cancer and viral disease. The company's platform uses artificial intelligence to design, detect, synthesize, and deliver identical peptides to stimulate therapeutic attacks by the patient's native immune system, enabling patients to have medicines that treat and prevent disease via selective T-cell stimulation.
Contact Information
Website
www.flowpharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 4829 Galaxy Parkway
- Suite K, Warrensville Heights
- Cleveland, OH 44128
- United States
+1 (216) 000-0000
Flow Pharma Timeline
Flow Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 02-Nov-2022 | $180K | 00.000 | Completed | Clinical Trials - General | |
| 6. Debt - PPP | 14-Apr-2020 | 00000 | 00.000 | Completed | Clinical Trials - General | |
| 5. Grant | 01-Jan-2020 | 00000 | 00.000 | Completed | Clinical Trials - General | |
| 4. Later Stage VC | 28-Feb-2018 | 00.000 | 00.000 | Completed | Startup | |
| 3. Seed Round | 28-Feb-2018 | 00.000 | 00.000 | Completed | Startup | |
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Angel (individual) | Completed | Startup |
Flow Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Flow Pharma Patents
Flow Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3169718-A1 | Injectable formulation of poly(lactic-co-glycolic (plga)) microspheres encapsulating siltuximab | Pending | 18-Mar-2020 | 00000000000 | |
| EP-4121069-A1 | Injectable formulation of poly(lactic-co-glycolic (plga)) microspheres encapsulating siltuximab | Pending | 18-Mar-2020 | 00000000000 | |
| US-20210292406-A1 | Controlled release of antibodies to modulate cytokines | Pending | 18-Mar-2020 | 00000000000 | |
| AU-2021239983-A1 | Injectable formulation of poly(lactic-co-glycolic (plga)) microspheres encapsulating siltuximab | Pending | 18-Mar-2020 | 0000000000 | |
| US-20200276288-A1 | Method of making a personalized cancer vaccine | Pending | 01-Mar-2019 | A61K39/0011 |
Flow Pharma Executive Team (6)
Flow Pharma Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Pamela Steele | Self | Board Member | 000 0000 |
| Stephen Farr Ph.D | Self | Board Member | 000 0000 |
| Thomas Brady | Flow Pharma | Vice President of Business Development & Executive Chairman | 000 0000 |
| Tikoes Blankenberg | Flow Pharma | Chairman | 000 0000 |
| Tunde Otulana MD | Self | Board Member | 000 0000 |
Flow Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Flow Pharma Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Small Business Innovation Research and Small Business Technology Transfer Programs | Government | 000 0000 | 000000 0 | ||
| United States Department of Defense | Government | 000 0000 | 000000 0 | ||
| Button Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Agility Labs | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
| Naveen Jain | Angel (individual) | Minority | 000 0000 | 000000 0 |
Flow Pharma Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 000 | 00000 0000 | Pharmaceuticals |